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Abstract
Background: Comparative trials evaluating management strategies for colorectal cancer liver metasta-
ses (CLM) are lacking, especially for older patients. This study developed a decision-analytic model to
quantify outcomes associated with treatment strategies for CLM in older patients.
Methods: A Markov-decision model was built to examine the effect on life expectancy (LE) and quality-
adjusted life expectancy (QALE) for best supportive care (BSC), systemic chemotherapy (SC),
radiofrequency ablation (RFA) and hepatic resection (HR). The baseline patient cohort assumptions
included healthy 70-year-old CLM patients after a primary cancer resection. Event and transition prob-
abilities and utilities were derived from a literature review. Deterministic and probabilistic sensitivity
analyses were performed on all study parameters.
Results: In base case analysis, BSC, SC, RFA and HR yielded LEs of 11.9, 23.1, 34.8 and 37.0 months,
and QALEs of 7.8, 13.2, 22.0 and 25.0 months, respectively. Model results were sensitive to age,
comorbidity, length of model simulation and utility after HR. Probabilistic sensitivity analysis showed
increasing preference for RFA over HR with increasing patient age.
Conclusions: HR may be optimal for healthy 70-year-old patients with CLM. In older patients with
comorbidities, RFA may provide better LE and QALE. Treatment decisions in older cancer patients should
account for patient age, comorbidities, local expertise and individual values.
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Introduction
There are over 39 million people in the US over the age of 65 years,
an increase of 13.2% since 2000.1 Furthermore, 54.7% of cancer
cases are diagnosed in patients over 65 years.2 Age-related
increases in cancer incidence and the growing geriatric population
is leading to increased numbers of older patients with cancer, the
second most deadly being colorectal carcinoma (CRC).
Colorectal liver metastases (CLM) develop in 50–60% of CRC
patients and are responsible for two-thirds of mortalities.3,4
Metachronous CLM represent approximately 71% of disease
recurrence in patients who underwent CRC resection, and are the
most frequent initial recurrence site.5,6 Survival with untreated
CLM is dismal and most patients die within a year after
diagnosis.7–10 Surgery offers the highest cure rate, approximately
40% at 5 years;11–15 however, novel strategies such as ablative thera-
pies and evolving chemotherapy agents are also effective.16
Primary modalities for CLM management include best sup-
portive care (BSC), systemic chemotherapy (SC), radiofrequency
ablation (RFA) and hepatic resection (HR). For older patients,
non-surgical therapies are often favoured, with the assumption
that surgical morbidity and mortality are unacceptable owing to
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comorbidities or advanced age. Safety and success of HR has
improved in the past two decades with careful patient selection,
advances in anaesthesia and better post-operative care,17 prompt-
ing investigations into HR in older patients;18–31 however, all
studies are single-centre retrospective studies with limited
numbers.
Management decisions for older patients with CLM is further
complicated by balancing comorbidities, which increased
treatment-related toxicity and competing causes of mortality,
quality of life (QoL) and risks of therapy. As there are no clear
guidelines and a randomized trial to examine this issue is unlikely,
we chose to assess the relative efficacies utilizing a Markov deci-
sion analysis (DA) methodology. The objective of this study was to
determine, from a patient perspective, the optimal strategy for the
management of older patients (age ≥ 70 years) who present with
liver metastases after primary CRC surgery. This study evaluated
commonly used strategies for treating older patients with CLM
using a decision-analytic model to determine gains in life expec-
tancy (LE) and quality-adjusted life expectancy (QALE). No other
study has focused on exploring treatment strategies specifically for
the elderly. As this question may never be answered with
randomized trials, this DA serves as a comprehensive synthesis of
the current available evidence.
Methods
Model design
A Markov state transition model was developed using TreeAge Pro
software (v2009; TreeAge Software, Inc., Williamstown, MA, USA)
to evaluate the effectiveness of BSC, SC, RFA and HR for treating
CLM in older patients. A Markov DA allows modelling outcomes
for clinical problems associated with continuous (e.g. risk of
recurrence/progression) as opposed to a one-time risk (e.g. risk of
peri-operative mortality). Furthermore, it allows for modelling
outcomes when the timing of events is important and when these
events may happen multiple times.32 The Markov DA assumes that
a patient is always in one of a finite number of health states and that
events are represented as transitions from one state to another. A
utility value, which is a QOL value on a 0–1 scale, is assigned to each
health state. The overall QALE is the sum of time spent in each
health state multiplied by the utility assigned to that health state.32
In our model, it is assumed that all patients present with CLM
after a resection of the primary colorectal lesion. This represents
the majority of patients who present with resectable CLMs.4,33 We
also assumed that patients entering the analysis have CLMs that
are amenable to all treatment options. This assumption allows fair
comparison between strategies as the invasive strategies each have
their own limitations such as the size of lesions for RFA and the
distribution of lesions for HR. In reality, patients who are not
amenable to all treatment options at presentation represent a
heterogeneous group for whom therapeutic choices are often
limited. A simulated patient is randomly allocated to one of four
different treatment options: (1) BSC; (2) SC; (3) RFA; or (4) HR.
Within a given treatment option, patients can only transition
from one health state to another once per cycle. The model was
simulated for 5 years using one-month cycle lengths with the
assumption that tumour recurrence will not be detected before
1 month.34
For the Markov DA model, several health states were defined for
the four different treatment modalities. All events of interest were
modelled as transitions between health states (Fig. 1). In the BSC
arm, all CRC liver metastases are left untreated and patients are
provided supportive care only. SC was defined as 5-FU, leucovorin
and irinotecan, currently the standard regimen for CLM, which
has established safety and efficacy in older patients.35–38 Severe
toxicity was defined as grade ≥ 3 toxicity according to the
Common Terminology Criteria for Adverse Events scale.39,40 An
assumption of our model is that chemotherapy is halted if a
patient develops severe toxicity and therefore there is no transition
from severe to no/mild toxicity. With each cycle, there is also a
probability that a patient transitions from no/mild toxicity to
severe toxicity. RFA and HR were built with a similar structure to
ensure model balance according to good modelling practice.41–45
Peri-procedural chemotherapy was not modelled as separate
strategies and was included in the analysis as part of RFA or HR.
Recurrence was defined as any local or metastatic disease progres-
sion and resulted in patients receiving non-invasive treatments
(i.e. BSC or SC) without repeat ablation or surgery. The choice of
entering the BSC or SC treatment arms after either RFA or HR was
related to the patient’s baseline co-morbidity (see below). A
number of patients entering our model were defined to have RFA
that was ineffective (inability to obtain complete oncologic clear-
ance and therefore was not performed) and thus proceeded to
receive BSC or SC. The effective and ineffective arms for RFA were
to reflect clinical practice and create a balance with the HR arms of
resectable and unresectable, respectively. Similarly, patients deter-
mined at the time of HR to have unresectable disease also pre-
ceded to BSC or SC. Treatment complications could impact
outcomes in two ways: they impart a disutility (i.e. loss of health-
related QoL) in the short term (3 months) and increase baseline
mortality in the long term (up to 24 months). At the start of each
simulated cycle, the patient can stay in their current treatment
modality or move to another, depending on transitional probabil-
ity (derived from probability of recurrence of 50% over
10 months), age and comorbidity.
The model was run until one of four conditions was met: (1) all
simulated patients have died; (2) all simulated patients reach
100 years of age, (3) incremental benefits gained per cycle have
become <0.001/cycle, or (4) 60 cycles (5 years) have passed. The
upper age limit of 100 years was necessary given the paucity of
reliable mortality data for patients older than 100 years. An incre-
mental utility gain of less than 0.001 per cycle was defined as
negligible in order to improve model efficiency. The 60-cycle
(5-year) limit was placed on our model in order to enhance clini-
cal relevance, as the lack of recurrence by 5 years after treatment
generally defines a cure.46 Another reason for this limit is the
scarcity of data on survival and recurrence rates after 5 years after
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RFA or HR. The half-cycle correction was applied to all health
states, after good modelling practice, in order to improve the
accuracy of expected value estimates.47
Age and comorbidities
Age ≥ 70 years was used to define older patients. This chronologi-
cal definition was chosen owing to its common use in geriatric
oncology studies.48,49 Patient comorbidities were defined using the
Charlson score, a weighted scoring system validated for predicting
morbidity and mortality in CRC patients with liver metastases.50
According to the overall score, patients were identified as having:
low (0), medium (1), or high (≥2) comorbidity. Our model
accounts for the effect of comorbidities in several ways. First, the
level of comorbidity alters the probability of dying from an inva-
sive procedure (RFA or HR). Previous studies in surgical oncology
have demonstrated increased post-procedural mortality associ-
ated with increasing comorbidity.51–53 Second, patients with high
comorbidity (Charlson score ≥2) were excluded from receiving
any systemic chemotherapy. Finally, our model accounts for the
effect of comorbidity burden on LE by applying a comorbidity
multiplier to standard life table mortality estimates.
We used a method first described by Welch et al., which used
the declining exponential approximation for life expectancy
(DEALE) model to quantify the effect of comorbidities on annual
mortality.54 The DEALE approximation assumes that, across any
short period of time, LE is equal to the inverse of the annual
mortality rate.55 By extension, one can calculate the average
annual mortality rate given any specific starting age by referring to
standard life tables (Table 1). Welch’s method then assumed that
healthier individuals have a longer LE and lower annual mortality
rates than the average person. Conversely, sicker individuals have
a shorter LE and thus higher mortality rates. For our model, we
assumed that our defined categories of low, medium and high
comorbidity translate to 75th, 50th and 25th percentiles of LE from
census data. We then calculated annual mortality using the
DEALE model described earlier. Life expectancy values were
derived from US census data specific to a 70-year-old individual.56
Finally, a comorbidity multiplier was derived using the medium
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comorbidity level (and thus median life expectancy) as the refer-
ence (Table 1). This application of the Welch method has been
used in other studies to approximate the impact of comorbidities
on life expectancies.57,58
Outcomes were measured in LE and QALE. Health-related QoL
was modelsed as utility values. In our model, utility was generally
defined by the individual’s state of well-being derived from the
preference one placed on being in that particular health state.59
Typically, utilities range from 0 (equivalent to death) to 1 (repre-
senting perfect health). The base-case for primary analysis was a
70-year-old patient with a Charlson’s comorbidity index of 0 (low
comorbidity), presenting with CLM after a CRC resection. As
tumour-specific criteria for RFA and HR are different and often
poorly supported by evidence,16 only patients with tumours
potentially treatable by either strategy were included.
Model data
Probabilities were obtained from literature reviews by searching
MEDLINE and EMBASE databases from 1950–2010 (Table 2).
Studies with the highest-grade evidence were used to derive base-
line probabilities. All sources were used to establish ranges for
sensitivity analysis. In cases of equal grade evidence, probabilities
were derived using an inverse variance-weighted pooling
method.60 This method is commonly employed in meta-analyses
where the weight given to each study is the inverse of the variance
of the effect estimate from each.60 This method gives heavier
weight to larger, as well as more precise, studies (i.e. with smaller
standard errors). This generally produces more accurate pooled
estimates than weighting by sample size alone. If parameter esti-
mates were obtained from one source, 95% confidence intervals
were used as ranges for sensitivity analyses. Where possible, data
specific to patients over 70 years were used. Age-adjusted mortal-
ity probabilities were derived from actuarial life tables to model
death from other causes.61 Hazard ratios for post-procedure mor-
bidity and mortality were obtained from studies where multivari-
ate regression was performed with both age and comorbidity as
significant covariates. This allowed us to separately estimate risks
for different age and comorbidity values.
Utility values were derived from a prospective study by Ruers
et al., who obtained health-related QoL data from 109 patients
with CLM before and after treatment with HR, ablation and SC.62
As a result of the paucity of utility data, ranges used in sensitivity
analysis were set as ±20% of the point estimates.
Model analysis
Only recurrence data were derived from our literature review;
survival statistics were not pre-specified in the model. Instead,
overall survival (OS) after RFA or HR reported in our literature
review served as data for external validation by comparing
reported survival-to-survival predicted by our model.
Base-case expected value calculations were performed in
deterministic (using fixed values from best evidence) and sto-
chastic (probability-based estimates using pre-specified distribu-
tions for each variable) manners. Significant differences between
strategies were defined as incremental gains in LE or QALE of >1
month.
Sensitivity analysis
For one-way deterministic sensitivity analyses, all parameters were
tested within the plausible range, and the entire range (for prob-
abilities and utilities). Variables are considered sensitive if the
preferred strategy (the one with maximum LE or QALE) changes
when the variable is changed within the specified range. For sen-
sitive variables in one-way analyses, threshold values are calcu-
lated to represent the value above or below which a different
strategy would be preferred. Ranges for sensitivity analysis were
derived from published literature as mentioned in previous sec-
tions and are presented in Table 2. In order to vary parameters in
the form of tables such as the probability of non-cancer death, a
multiplier set to a baseline of 1 was applied to such parameters to
be used in the sensitivity analysis.
Two-way sensitivity analysis follows the same principles as one-
way analyses except that two parameters are varied simultaneously
through their specified ranges whereas all others remain constant.
These provide additional information regarding the effects of
uncertainty on the model outputs. However, owing to the sheer
number of combinatorial pairs of variables available for analysis,
two-way sensitivity analyses were reserved for continuous vari-
ables that were sensitive in the one-way analyses as well as vari-
ables hypothesized to be clinically important.
Therefore, for all parameters in a deterministic sensitivity
analysis, except utilities, one-way analyses were performed on the
LE model. Analyses for utilities used the QALE model. Two-way
sensitivity analyses were performed on all clinically meaningful
variables and those sensitive in one-way analyses.
Probabilistic sensitivity analysis was carried out on stochastic
versions of our model to simultaneously evaluate the combined
Table 1 Calculation of comorbidity multiplier
Life expectancya Annual mortality Charlson's index Level of comorbidity Comorbidity multiplierb
Percentile Years
75th 19.65 0.051 0 Low 0.715
50th 14.05 0.071 1 Medium 1
25th 8.1 0.123 ≥2 High 1.735
aPercentiles and remaining life expectancy derived from Life Tables of the United States.56
bThis modifies the annual probability of dying from other causes (Annual Mortality column in the table).
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uncertainty of all variables in the model. This produces point
estimates and standard deviations for the base case and estima-
tions of strategy selection frequency. In cases where competing
strategies provided <1 month of incremental gain, the result was
defined as ‘indifferent.’ Uncertainty was assessed using 10 000 s-
order Monte Carlo simulations sampling all parameter distribu-
tions. This allows us to generate 95% credible intervals for LE and
QALE estimates for each strategy.
Table 2 Model parameters – baseline estimates, ranges and one-way sensitivity analysis
Variable Baselinea Rangea Threshold within
(outside of) rangeb
Strategy preferred below/
above thresholdc
Reference
Global Variables
Age at diagnosis (years) 70 70–90 79.4 HR/RFA –
Comorbidity by Charlson's Index 0 0–3 >2 HR/RFA –
Length of simulation (months) 60 12–120 39.3 RFA/HR –
Probabilities
Procedure Success
RFA (Effectiveness)d 0.929 0.920–0.938 NT (NT) – 64,67,68,70,71,73
HR (Resectability)d 0.908 0.900–0.916 NT (0.790) (RFA/HR) 85–92
Death
Non-cancer deatha Life Tablese 0.5–1.5 x Table NT (2.7 x Table) (HR/RFA) 61
On BSCa 0.0803 0.0719–0.0887 NT (0.0178) (BSC/HR) 7
On SCa 0.0386 0.0346–0.0437 NT (0.0270) (RFA/HR) 93
RFA (operative) 0.003 0–0.01 NT (NT) – 63–73
HR (operative) 0.041 0.034–0.048 NT (0.104) (HR/RFA) 18,19,21–28,30,31,74
Laparotomy (operative) 0.037 0.019–0.056 NT (NT) – 94
Recurrence
RFAa 0.0642 0.0518–0.0766 NT (0.0496) (RFA/HR) 63,68,70,71,73
HRa 0.0248 0.0192–0.0304 NT (0.0318) (HR/RFA) 18,19,21,23,25–28,74
Complications
RFA 0.036 0.030–0.042 NT (NT) – 64–66,68–73
HR 0.350 0.333–0.367 NT (0.553) (HR/RFA) 18,19,21–24,26–28,31,74
Laparotomy 0.224 0.112–0.448 NT (NT) – 94
Severe toxicity on SC 0.25 0.125–0.375 NT (NT) – 95
Modifying ratiosb
Non-cancer death (by comorbidity) Tablee 0.5–1.5 x Table NT (2.7 x Table) (HR/RFA) Assumption
Procedural mortality (by comorbidity) Tablee 0.5–1.5 x Table NT (2.8 x Table) (HR/RFA) 96
Mortality after complications (by time) Tablee 0.5–1.5 x Table NT (2.6 x Table) (HR/RFA) 97
Utilitiesf
BSC 0.66 0.53–0.79 NT (NT) – Assumption
SC (no/mild toxicity) 0.60 0.48–0.72 NT (0.90) (HR/RFA) 62
SC (mod/severe toxicity)g 0.48g – – – Assumption
RFA 0.72 0.58–0.86 NT (0.90) (HR/RFA) 62
HR 0.72 0.58–0.86 0.60 RFA/HR 62
Complications HR/RFA/laparotomy 0.60 0.48–0.72 NT (NT) – 62
Death 0 – – – –
aAll transitional probabilities listed as per-month equivalents.
bProbabilities and utilities were varied within the plausible range as well as full range of 0 to 1.
cStrategies within parentheses are for situations where the preferred treatment switch occurs at a threshold that is outside the plausible range.
dProbability listed as an absolute value.
eAll variables derived from tables were varied at ±50% of the values retrieved from tables.
fRanges for all utilities are given as ±20% of baseline. See text for further details.
gThis utility is always linked to the utility value for ‘chemotherapy with no/mild toxicity’ by a factor of 0.8X.
NT, no threshold; HR, hepatic resection; RFA, radiofrequency ablation; BSC, best supportive care; SC, systemic chemotherapy.
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Internal and external model validation
Once our final model was constructed, we performed rigorous
internal testing to ensure its integrity and internal validity. We
began by examining each branch of the model for syntax errors.
After this, all variables were tested using null to extreme inputs (0
to 1 for probabilities and utilities) to ensure that obvious and
predictable outputs were produced.
Our model was built on the assumption that recurrences after
invasive treatments precede and account for all cancer-related
deaths. As we also accounted for non-cancer deaths explicitly,
combining these two causes of death allowed us to estimate overall
survival. External validation was performed by comparing OS
predicted by our model with OS reported in our literature review.
Using baseline cohort analysis, survival curves for each strategy
of our model were generated using the Declining Exponential
Approximation of Life Expectancy (DEALE) technique.54 The
resulting median OS data produced by the model were compared
with published OS data from our literature review. This validation
was not performed with the SC and BSC strategies as OS data
from the literature were used in our modelling of those strategies.
Results
The LE model was used to predict median, 3-, and 5-year OS for
RFA (33 months, 45% and 20%, respectively) and HR (37 months,
51% and 33%, respectively, for our base-case cohort of patients).
These predicted values agree with ranges of published
data,18,19,21–28,30,31,63–74 supporting external validity of our model.
Deterministic base case-analysis resulted in LE of 11.9, 23.1,
34.8 and 37.0 months, and QALE of 7.8, 13.2, 22.0 and 25.0
months for BSC, SC, RFA, and HR strategies, respectively. Based
on a 70-year-old patient with no comorbidities and base-case
estimations of each parameter, HR offered the most LE and QALE
over a 5-year period. All incremental gains between strategies were
>1 month, and thus clinically significant. HR provided incremen-
tal benefits of 2.3 months of LE and 3 months of QALE over RFA.
The ranking of preferred strategies did not change between LE
and QALE analyses.
Deterministic sensitivity analysis
Our model was sensitive to four parameters within plausible
ranges: age at diagnosis, comorbidity, length of simulation and
utility after HR (Table 2). Four additional variables, recurrence
post-RFA, recurrence post-HR, utility of SC and utility of well-
state post-RFA, produced threshold values close to, but outside
plausible ranges.
HR was also preferred for patients up to 79 years old, after
which RFA was preferred (Fig. 2). Differences in LE offered by HR
versus RFA ranged from a gain of 2.3 months for 70 year olds to a
loss of 3.7 months for 90 year olds.
HR was preferred in healthier patients. Patients with high
comorbidity benefited more from RFA than HR in both LE and
QALE gains. However, the benefit of RFA over HR in patients with
high comorbidity was only 0.8 months of LE and 0.2 months of
QALE, and thus not clinically significant. In contrast, based on a
70-year-old patient with no/mild comorbidities, HR provided an
incremental benefit of 3 months of QALE over RFA over 5 years of
follow-up. In addition, the ranking of preferred strategies did not
change between LE and QALE analyses.
By varying the simulation length from 12 to 120 months, a
threshold value was identified at 39.3 months, after which HR was
preferred over RFA (Fig. 3). LE gains from RFA and HR were
equivalent under 39.3 months. Beyond 50 months of simulation,
LE gains from HR over RFA became significant. At 120 months, a
benefit of 8.3 months from HR over RFA was predicted.
Although probabilities of recurrence after RFA and HR were
not sensitive variables in initial sensitivity analyses using pub-
lished ranges, there was a trend towards both parameters having
an impact on model outcomes (Table 2). Our analysis demon-
strated that at a monthly probability of recurrence after RFA of
0.0496, RFA and HR provided equivalent outcomes. This thresh-
old value is within 4.2% of the lowest published post-RFA recur-
rence data. Likewise, the threshold value associated with the
monthly probability of recurrence after HR was 0.0318, 1.3%
greater than the highest published post-HR recurrence value.
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The only sensitive utility variable was utility after HR. In spite of
a calculated threshold-value of 0.60, the maximum benefit of RFA
over HR was 0.5 months and thus not clinically significant. In
extended sensitivity analysis allowing ranges of 0 to 1, incremental
benefits of one strategy over another did not reach significance.
When tested in two-way sensitivity analysis with age, utility after
HR and RFA became increasingly sensitive parameters with
increasing age (Fig. 4).
Probabilistic sensitivity analysis
Compared with deterministic analysis, while the ranking of pre-
ferred strategies did not change in probabilistic analysis, there was
no significant difference in outcomes between RFA and HR.
However, both RFA and HR were significantly better than SC and
BSC (Fig. 4).
At age 70 years, HR and RFA were preferred in 62.7% and
15.1% of simulations when assessing LE, and 64.6% and 21.4%
when assessing QALE, respectively. At age 80 years, preferences for
HR and RFA were 25.8% and 46.3%, respectively, in the LE model;
32.0% and 50.5%, respectively, in the QALE model. At age
90 years, preferences for HR and RFA were 1.6% and 91.3%,
respectively, in the LE model; 23.9% and 55.0%, respectively, in
the QALE model (Fig. 5). SC and BSC were never the preferred
strategy.
Discussion
Older patients diagnosed with CLM after a resection of primary
CRC pose a difficult clinical scenario for patients and treating
clinicians. While increasing evidence demonstrates that patients
should not be denied aggressive treatments based on chronologi-
cal age alone,75–78 clinical judgements for older patients remain
complex and must consider published evidence, physiological
changes of aging, comorbidities and patient values. Traditional
therapies of HR and 5-FU-based SC have improved, and are safe
and effective in older patients.79 The emergence of ablative thera-
pies such as RFA has been associated with minimal morbidity and
mortality; however, long-term effectiveness as monotherapy for
CLM is unclear.80 Finally, BSC may provide good QoL without
exposing patients to toxicities of cancer treatment. In the absence
of good quality trial data to guide clinical decision-making, we
built a Markov transition-state DA model to estimate outcomes of
BSC, SC, RFA and HR when used to treat CLM in older patients.
Overall, this study demonstrates superiority of RFA and HR
over non-invasive therapies in our mathematical model analyses.
However, patient age was crucial to selecting the optimal treat-
ment approach. Specifically, HR was significantly better than RFA
for a 70-year-old patient, providing gains of 2.3 months of LE and
3.0 months of QALE. However, the 2.3-month advantage of HR
over RFA at age 70 years became a 3.7-month disadvantage at age
90 years. This 6-month change in incremental LE suggests the
significant impact of age as a key factor in decision-making, rep-
resenting a contradiction to the notion that, in the absence of
comorbidity differences, patients should receive identical treat-
ments regardless of age.
In our sensitivity analyses, it is worthy to note that BSC and SC
were never the preferred options. For RFA versus HR, there was an
increasing preference for RFA with older age, especially in the LE
model versus the QALE model (Fig. 5).
Furthermore, our decision model focuses on disentangling the
effects of age and comorbidity on short- and long-term outcomes.
With respect to age, our key assumption is that, independent of
comorbidity, increasing age (within the range of 70–90 years) is
not associated with increased short-term treatment-related
complications. Instead, these complications are a function of tech-
nique, operator and comorbidity. Age increases the risk of long-
term death from non-cancer causes, which we have modelled
explicitly using life tables (Table 1). Increasing comorbidity is
assumed to be associated with increased short-term treatment-
related complications as well as long-term death from non-cancer
causes. In addition, high comorbidity is associated with avoidance
of systemic chemotherapy.
Compared with HR, RFA remains superior in terms of safety, as
evidenced by the minimal procedural mortality observed in
studies.67 Although HR still provided better efficacy, the combined
safety and efficacy of RFA has made it an attractive alternative to
HR in our model (in spite of a higher recurrence risk). Addition-
ally, our results suggest that while HR is preferred over RFA in
healthy older patients, these benefits decrease with increasing age
and comorbidities, which is suggested by a more gradual prefer-
ence for RFA with increasing age and comorbidity. It is conceiv-
able that the reduced recurrence rates associated with HR do not
result in significant long-term benefits in these oldest patients
because of competing mortality risks from non-cancer causes.
Similar impacts of comorbidities on treatment have been demon-
strated in other studies.51–53,81,82 Furthermore, as independent
variables, utilities do not significantly alter strategy selection.
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Figure 4 Impact of quality of life after a hepatic resection and age at diagnosis on preferred treatment strategy. HR, hepatic resection; RFA,
radiofrequency ablation
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Nonetheless, when we analysed the interaction of utility variables
with age, the resulting trends indicate that utility estimates (i.e.
patient preferences) become more important for older patients.
Practically, what this suggests is that QoL differences between
treatment options generally do not alter decision-making in this
disease. However, clinicians managing older patients should be
aware of patients’ values and expectations, particularly among the
very elderly. Our finding that significant survival differences
between RFA and HR only become evident after 50 months of
simulation may have implications on research. Future compara-
tive studies of RFA and HR efficacy should ensure sufficient
follow-up times of >4 years to show meaningful results, as shorter
comparative trials with insufficient follow-up may unfairly favour
RFA over HR.
This study has several limitations. First, there is a paucity of
high-quality literature regarding treatment of CLM in older
patients. Although randomized control trials represent the highest
level of evidence, very few have been performed comparing the
various therapies for CLM in older patients, making it a limitation
for such a decision analysis. While careful selection and summary
of all available evidence was performed, for these reasons, the
inclusion of non-randomized trials was an appropriate strategy to
extend the source of evidence. Aware of potential data inaccuracy,
we performed extensive sensitivity analyses around variable esti-
mates. Second, only four mutually exclusive strategies were
included in our model. In reality, there has been increasing focus
on multi-modal management of CLM; however, these approaches
are case-specific and have not been systemically studied among
older patients. Furthermore, rather than modelling every possible
treatment combination, our objective was to evaluate the most
commonly used modalities and develop a structural framework
upon which future models can be built. Patients with severe
comorbidity (Charlson’s scores ≥2) were excluded from receiving
chemotherapy in the model. This may have impacted sensitivity
analyses; however, it should not affect LE or QALE for HR and
RFA. Additionally, SC was never a preferred strategy in our analy-
ses. Utility data were derived from one study62 where all patients
underwent a laparotomy followed by HR, ablation or SC. This is
not the clinical scenario described in this model; however, these
data are a valuable starting point for linking LE with QoL in older
patients. Clearly further studies of patient utilities in the CLM
setting would be welcomed. Finally, on review of the literature,
there are very few studies that examine outcomes after more than
two attempts at repeat curative intent HR/RFA for colorectal
cancer liver metastasis. This reflects that repeat attempts at cura-
tive surgery remains a novel approach at managing colorectal liver
metastases and is certainly not the standard of care for recurrent
disease at this point, particularly for very elderly patients. There-
fore, repeat HR/RFA were not incorporated in our analysis but
may need to be considered in the future as the evidence base
matures.
The significance of our base-case results of HR over RFA in LE
(2.3 months) and QALE models (3.0 months) must be interpreted
in the correct context. Such values are often misinterpreted as
minimal increases in life span.83 In reality, LE and QALE represent
shifts of entire survival curves of a cohort of individuals and
incremental gains represent an increase in the probability of sur-
vival at any time point. Additionally, gains in LE and QALE
observed in our study are similar in magnitude to OS benefits
reported in SC trials for CLM.35,36,84
DA is useful in this field owing to its ability to explicitly incor-
porate factors such as age, comorbidity, treatment-specific factors
and patient values into a comprehensive model. It is often the lack
of high-quality, randomized evidence that necessitates the use of
DA as a synthesis of available evidence in a rational, quantitative
structure. Using a detailed decision analytic model populated with
current clinical data, our study suggests that RFA and HR are
superior to BSC and SC in terms of LE and QALE in older adults.
Moreover, these results highlight the importance of considering
both age and comorbidity when choosing between RFA and HR.
HR may provide a marginal benefit over RFA in healthy patients
aged 70–79 years whereas RFA may be more appropriate for older
patients with comorbidities and those aged 80 years or older. This
may potentially improve patient-physician communication and
informed decision-making in the clinical setting.
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